AstraZeneca posted its third-quarter and nine-month figures well before market open that day. These revealed that the company ...

Cancer drugs are booming, obesity bets are rising, and a Trump deal just locked in three years of tariff-free growth.

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.

AstraZeneca reported a significant 77% surge in quarterly net profit, reaching $2.53 billion, driven by strong US growth and ...

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

AstraZeneca chief exec Pascal Soriot (pictured) said Britain should be trying to attract cash from the pharmaceutical sector ...

AstraZeneca PLC (AZN) reports an 11% revenue increase, driven by oncology and biopharmaceuticals, while navigating R&D ...

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

The UK drugmaker struck a deal with President Donald Trump in October that will see the company reduce prices for some medicines and launch new products in the US at the same cost as in other wealthy ...